Tamer I. Khayal - Jul 13, 2023 Form 4 Insider Report for TransMedics Group, Inc. (TMDX)

Role
Chief Commercial Officer
Signature
By: /s/ Stephen Gordon, Attorney-in-Fact
Stock symbol
TMDX
Transactions as of
Jul 13, 2023
Transactions value $
-$420,103
Form type
4
Date filed
7/17/2023, 04:31 PM
Previous filing
Apr 25, 2023
Next filing
Jul 19, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction TMDX Common Stock Options Exercise $48K +2.97K +20.69% $16.14* 17.3K Jul 13, 2023 Direct F1
transaction TMDX Common Stock Sale -$268K -2.97K -17.14% $90.05 14.4K Jul 13, 2023 Direct F1, F2, F3
transaction TMDX Common Stock Sale -$200K -2.23K -13.09% $90.02 14.8K Jul 13, 2023 By the Khayal Family 2021 Irrevocable Trust F4, F5
holding TMDX Common Stock 11.1K Jul 13, 2023 By the Tamer Ibrahim Ahmed Khayal Trust

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction TMDX Stock Option (Right to Buy) Options Exercise $0 -2.97K -12.28% $0.00 21.2K Jul 13, 2023 Common Stock 2.97K $16.14 Direct F1, F6
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The reported transactions were effected pursuant to a Rule 10b5-1 trading plan entered into on December 2, 2022.
F2 The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $90.00 to $90.23, inclusive. The Reporting Person undertakes to provide to the Company, any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
F3 Includes 13,075 restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock.
F4 The reported transactions were effected pursuant to a Rule 10b5-1 trading plan entered into on December 12, 2022.
F5 The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $90.00 to $90.23, inclusive. The Reporting Person undertakes to provide to the Company, any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range
F6 The option vests at a rate of 2.0833% of the total number of shares each month until the option is fully vested on the fourth anniversary of the vesting commencement date, February 27, 2020.